RKV — Rakovina Therapeutics Share Price
0.000.00%
Last trade - 00:00- CA$6.34m
- CA$7.48m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.06 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -68.32% | ||
| Return on Equity | -89.48% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. The Company is focused on the development of new cancer treatments based on novel deoxyribonucleic acid (DNA)-damage response technologies. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- May 6th, 2019
- Public Since
- February 7th, 2020
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 140,792,575
- Address
- 105 - 1008 Beach Avenue, Vancouver, V6E 1T7
- Web
- https://www.rakovinatherapeutics.com/
- Phone
- +1 6046190225
- Auditors
- Davidson & Co LLP
Upcoming Events for RKV
Q1 2025 Rakovina Therapeutics Inc Earnings Release
Rakovina Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Rakovina Therapeutics Inc Earnings Release
Similar to RKV
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
What is the Rakovina Therapeutics share price?
As of Today at 22:50 UTC, shares in Rakovina Therapeutics are trading at CA$0.05. This share price information is delayed by 15 minutes.
How has the Rakovina Therapeutics share price performed this year?
Shares in Rakovina Therapeutics last closed at CA$0.05 and the price had moved by -44.44% over the past 365 days. In terms of relative price strength the Rakovina Therapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -50.61% over the past year.
What are the analyst and broker recommendations for Rakovina Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Rakovina Therapeutics dividend yield?
Rakovina Therapeutics does not currently pay a dividend.
Does Rakovina Therapeutics pay a dividend?
Rakovina Therapeutics does not currently pay a dividend.
When does Rakovina Therapeutics next pay dividends?
Rakovina Therapeutics does not currently pay a dividend.
How do I buy Rakovina Therapeutics shares?
To buy shares in Rakovina Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Rakovina Therapeutics?
As of the previous close price of CA$0.05, shares in Rakovina Therapeutics had a market capitalisation of CA$6.34m.
Where are Rakovina Therapeutics shares listed?
Here are the trading details for Rakovina Therapeutics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: RKV
What kind of share is Rakovina Therapeutics?
Based on an overall assessment of its quality, value and momentum Rakovina Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Rakovina Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Rakovina Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rakovina Therapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -33.72%.
As of the last closing price of CA$0.05, shares in Rakovina Therapeutics were trading -60.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Rakovina Therapeutics PE Ratio?
The Rakovina Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Rakovina Therapeutics?
We do not have data on Rakovina Therapeutics' directors